Real-World study checks Tivozanib's performance in kidney cancer
NCT ID NCT07354282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked back at the medical records of 200 patients with advanced clear cell kidney cancer who received Tivozanib as their first treatment. The goal was to see how long patients went without their cancer getting worse and how long they lived overall. The study focused on patients considered to have a favorable outlook based on a standard risk score.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tivozanib
What this could lead to
If results are positive, this could confirm that Tivozanib is a good first-line option for certain patients with advanced kidney cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only looks back at past data and cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundacion Jimenez Diaz
Madrid, Madrid, Spain
-
Hospital Gregorio Marañon
Madrid, Madrid, Spain
-
Hospital Lucus Augusti
Lugo, Galicia, Spain
-
Hospital Parc Tauli
Sabadell, Catalonia, Spain
-
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
-
Hospital Reina Sofia
Córdoba, Andalusia, Spain
-
Hospital Severo Ochoa
Leganés, Madrid, Spain
-
Hospital Vall de Hebron
Barcelona, Catalonia, Spain
-
Hospital Virgen de la Victoria
Málaga, Andalusia, Spain
-
Hospital Virgen del Rocio
Seville, Andalusia, Spain
-
Hospital de Burgos
Burgos, Castille and León, Spain
-
Hospital de Leon
León, Castille and León, Spain
-
Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat
L'Hospitalet de Llobregat, Catalonia, Spain
-
Instituto Valenciano de Oncologia (IVO)
Valencia, Valencia, Spain